ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 031,18
-0,42%
Dow Jones
38 386,09
0,00%
DAX
17 994,04
-0,76%
Brent Oil
87,535
0,29%
Bitcoin
61 144,57
-4,22%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Alterity Therapeutics Limited (ATHE)

  7. Alterity Therapeutics Limited (ATHE) Actualités

ATHE Alterity Therapeutics Limited

2,22
0,025 (1,14%)
Avant marché
Dernière mise à jour : 14:27:12
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Alterity Therapeutics Limited ATHE NASDAQ Certificat de dépôt
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,025 1,14% 2,22 14:27:12
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
2,195
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
30/4/202413:25GLOBEAppendix 4C – Q3 FY24 Quarterly Cash Flow Report
29/4/202413:25GLOBEAlterity Therapeutics Presents New Data Demonstrating..
17/4/202413:25GLOBEAlterity Therapeutics Parkinson’s Disease and Multiple..
10/4/202413:25GLOBEAlterity Therapeutics to Present New Data on ATH434 at the..
26/3/202415:25GLOBEAlterity Therapeutics Receives a A$3.9 Million Research &..
20/2/202416:25GLOBEAlterity Therapeutics to Present New Data at the Upcoming..
15/2/202423:29EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/2/202423:28EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/2/202413:25GLOBEAlterity Therapeutics Phase 2 Data Monitoring Committee..
31/1/202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/1/202413:24GLOBEAlterity Therapeutics to Participate in the ShareCafe Hidden..
22/1/202413:25GLOBEAlterity Therapeutics Issues Shareholder Letter Highlighting..
22/1/202412:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/1/202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/1/202423:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/1/202423:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/1/202412:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202414:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202414:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202414:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/1/202412:27EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/1/202412:24EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/1/202414:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/1/202414:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/1/202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/12/202314:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/12/202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/12/202314:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/12/202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/12/202306:30GLOBEAlterity Therapeutics Appoints Phillip Hains as Chief..
04/12/202322:35GLOBEAlterity Therapeutics to Host Webcast to Discuss ATH434..
04/12/202313:25GLOBEAlterity Therapeutics Reports Positive Efficacy Data for..
27/11/202313:25GLOBEAlterity Therapeutics Announces Presentation of Novel..
16/11/202313:25GLOBEAlterity Therapeutics Announces Presentation of New Data..
08/11/202313:25GLOBEAlterity Therapeutics Completes Enrolment in ATH434-201..
30/10/202312:25GLOBEAppendix 4C – Q1 FY24 Quarterly Cash Flow Report
26/10/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
13/9/202312:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/8/202313:25GLOBEAlterity Therapeutics Presents New Data on Multiple System..
23/8/202313:25GLOBEAlterity Therapeutics Granted New Composition of Matter..
22/8/202313:25GLOBEAlterity Therapeutics Rare Disease Natural History Study to..
15/8/202313:25GLOBEAlterity Therapeutics Receives a $4.74 million Research &..
31/7/202313:52GLOBEAppendix 4C – Q4 FY23 Quarterly Cash Flow Report
26/7/202313:25GLOBEAlterity Therapeutics Phase 2 Data Monitoring Committee..
21/6/202313:25GLOBEAlterity Therapeutics to Present in MST Access Rare..
30/5/202313:25GLOBEAlterity Therapeutics Initiates Second Phase 2 Study in Rare..
19/5/202313:25GLOBEAlterity Therapeutics CEO David Stamler to Present at the..
10/5/202313:25GLOBEAppendix 4C – Q3 FY23 Quarterly Cash Flow Report

Dernières Valeurs Consultées

NASDAQ
ATHE
Alterity Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés